This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).

Phase 3

Completed

• Conditions: Health Condition 1: null- Acute Coronary SyndromeAtherosclerosisCardiovascular DiseaseCoronary Heart Disease

• Registration Number: CTRI/2010/091/000212
• Lead Sponsor: GlaxoSmithKline Research and Development Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 11500

Inclusion Criteria

1.Signed written informed consent.

2.Men or women at least 18 years old (in Taiwan, at least 20 years old). Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.

3.Hospitalization for acute coronary syndrome (ACS) within 30 days prior to study entry.

4.Clinically stable for 24 hours prior to study entry.

5.A planned percutaneous coronary intervention (PCI) should be performed prior to study entry, whenever possible.

6.At least one of the following:

7.At least 60 years old.

8.Myocardial infarction prior to the qualifying ACS event.

9.Diabetes mellitus requiring treatment with medication.

10.Diagnosed mild or moderate reduction in kidney function.

11.Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral artery disease.

Exclusion Criteria

1.ACS symptoms or lab results not believed to be caused by a narrowing or blocked coronary artery.

2.No major coronary artery with a blockage of more than 50% (unless all stenoses are successfully treated by PCI).

3.Planned coronary artery bypass graft (CABG) surgery, or CABG surgery performed after the qualifying ACS event and prior to study entry.

4.Certain types of liver disease.

5.Severe reduction in kidney function OR removal of a kidney OR kidney transplant.

6.Severe heart failure.

7.Blood pressure higher than normal despite lifestyle changes and treatment with medications.

8.Any life-threatening disease with a life expectancy of less than 2 years (other than heart disease) that may prevent the subject from completing the study.

9.Severe asthma that is poorly controlled with medication.

10.Pregnancy (Note: A pregnancy test will be performed on all non-sterile women prior to study entry).

11.Previous severe allergic reaction to food, medications, drink, insect stings, etc.

12.Drug or alcohol abuse within the past 6 months. Mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.

13.Certain medications that may interfere with the study medication (these will be identified by the study doctor).

14.If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, must have a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity less than or equal to 20.0 nmol/min/mL are excluded.

15.Previously took darapladib (SB-480848).

16.Participation in a study of an investigational medication within the past 30 days.

17.Current participation in a study of an investigational device.

18.Any other reason the investigator deems the subject should not participate in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to the first occurrence of any component of the composite of Major Adverse Cardiovascular Events [MACE: CV death (death due to a cardiovascular cause), non-fatal myocardial infarction, non-fatal stroke].Timepoint: Through the end of the study.

Secondary Outcome Measures

Name	Time	Method
1.The composite measure of major coronary events that include the time to first occurrence of coronary heart disease death, non-fatal myocardial infarction or urgent coronary revascularization for myocardial ischemia.Timepoint: Through the end of the study.;2.The composite measure of total coronary events that include the time to first occurrence of coronary heart disease death, non-fatal myocardial infarction, hospitalization for unstable angina, or any coronary revascularization procedure.Timepoint: Through the end of the study.;3.The time to individual components of MACE [cardiovascular death, myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal)].Timepoint: Through the end of the study.;4.All cause mortality.Timepoint: Through the end of the study.;5.The time to the first occurrence of any component of the composite of all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke.Timepoint: Through the end of the study.